Medpace Holdings, Inc. $MEDP Shares Sold by Vulcan Value Partners LLC

Key Points

• Vulcan Value Partners cut its Medpace position by 76.4% in the fourth quarter, leaving it with 47,306 shares worth about $26.6 million.
• Medpace is facing a class-action lawsuit over alleged misleading disclosures about cancellation rates and book-to-bill ratio, with multiple law firms highlighting a June 8 lead-plaintiff deadline.
• The company recently beat quarterly earnings and revenue estimates, but sentiment remains mixed: its shares were down slightly, an insider sold a large stake, and analysts now have a consensus Hold rating with a $467.08 average price target.

Vulcan Value Partners LLC lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 76.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 47,306 shares of the company's stock after selling 152,866 shares during the period. Medpace makes up 0.5% of Vulcan Value Partners LLC's holdings, making the stock its 28th biggest holding. Vulcan Value Partners LLC owned approximately 0.17% of Medpace worth $26,580,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in shares of Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock valued at $374,836,000 after purchasing an additional 24,625 shares in the last quarter. King Luther Capital Management Corp grew its holdings in Medpace by 4.2% during the 4th quarter. King Luther Capital Management Corp now owns 18,331 shares of the company's stock worth $10,296,000 after acquiring an additional 739 shares in the last quarter. Jackson Creek Investment Advisors LLC acquired a new position in Medpace during the 4th quarter worth approximately $1,286,000. Fisher Asset Management LLC grew its holdings in Medpace by 0.8% during the 4th quarter. Fisher Asset Management LLC now owns 138,799 shares of the company's stock worth $77,957,000 after acquiring an additional 1,053 shares in the last quarter. Finally, Clearstead Advisors LLC grew its holdings in Medpace by 13.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,353 shares of the company's stock worth $760,000 after acquiring an additional 165 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Several firms, including Rosen, Glancy Prongay, Levi & Korsinsky, Schall, Pomerantz, and others, issued reminders about the ongoing class action and the June 8 lead-plaintiff deadline, keeping legal overhang front and center for shareholders. Article Title
• Negative Sentiment: One lawsuit notice specifically highlights allegations that Medpace misled investors about cancellation rates and book-to-bill ratio, and references a prior 16% stock drop tied to those disclosures, reinforcing fears of further liability or reputational damage. Article Title
• Neutral Sentiment: Zacks published a comparison of Medpace versus Labcorp on valuation, which may influence investor sentiment only modestly and does not appear to be a major stock-moving catalyst. Article Title

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the company's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 20.50% of the company's stock.

Medpace Trading Down 0.3%

Shares of Medpace stock opened at $428.00 on Thursday. The company has a fifty day simple moving average of $457.76 and a 200-day simple moving average of $515.44. Medpace Holdings, Inc. has a 12-month low of $291.28 and a 12-month high of $628.92. The stock has a market cap of $12.22 billion, a price-to-earnings ratio of 26.90, a PEG ratio of 2.18 and a beta of 1.19.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to analysts' expectations of $697.82 million. During the same quarter in the prior year, the business posted $3.67 EPS. The company's revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on MEDP. Wall Street Zen cut shares of Medpace from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. TD Cowen upgraded shares of Medpace from a "sell" rating to a "hold" rating and lowered their price target for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Jefferies Financial Group upgraded shares of Medpace from a "hold" rating to a "buy" rating and set a $560.00 price target for the company in a report on Friday, February 13th. Truist Financial lowered their price target on shares of Medpace from $555.00 to $539.00 and set a "hold" rating for the company in a report on Wednesday, February 11th. Finally, BMO Capital Markets lowered their price target on shares of Medpace from $460.00 to $400.00 and set a "market perform" rating for the company in a report on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $467.08.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.